Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Summary

This study evaluates the addition of dapagliflozin in the treatment of type 2 diabetes with metformin and evogliptin combination therapy. Half of subjects will receive dapagliflozin, metformin and evogliptin, while the other half will receive placebo, metformin and evogliptin.

Timeline

Start

2020-05-26

Primary completion

2022-02-23

Completion

2022-02-23

Outcome

Met primary endpoint

paper At Week 24, dapagliflozin significantly reduced HbA1c levels. PMID 39223856 ↗

paper The least squares mean difference in HbA1c level change from baseline after 24 weeks of treatment was -0.70% (-7.7 mmol/mol) (p < 0.0001). PMID 39223856 ↗

Publications

• Jeong IK, Choi KM, Han KA, Kim KA, Kim IJ, Han SJ, Lee WY, Yoo SJ. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2024 Nov;26(11):5065-5077. doi: 10.1111/dom.15838. Epub 2024 Sep 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral
Background	Evogliptin	Small molecule	5 mg	Oral
Background	Metformin	Small molecule	1000 mg	Oral

Indications